Impact of weight loss drugs on medical devices and food and beverage stocks waning
<img width="250" height="167" src="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" decoding="async" style="float: left; margin-right: 5px;" link_thumbnail="" srcset="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg 250w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-700×466.jpg 700w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-768×512.jpg 768w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-120×80.jpg 120w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-245×163.jpg 245w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-500×333.jpg 500w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819.jpg 1255w" sizes="(max-width: 250px) 100vw, 250px" /><p><span data-contrast="auto">Sales of Novo Nordisk’s (NVO) diabetic drug, Ozempic, escalated by more than $1bn between its $2.3bn in Q3 2022 and $3.5bn in Q3 2023. Yahoo Finance noticed the absence of any discussions around GLP-1s at two conferences. A <a href="https://www.leaprate.com/financial-services/forecasters-predicting-a-strong-annual-performance-for-jpmorgan/" target="_blank" rel="noopener">JPMorgan</a> analyst, who attended a healthcare conference in January 2024, viewed this as good news for the medical devices sector and wrote in a note:</span><span data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"> </span></p>
<blockquote><p><span data-contrast="auto">Thankfully, what we didn’t hear was mention of GLP-1s – that bubble of fear and panic seems to have burst for the most part.</span></p></blockquote>
<p><span data-contrast="auto">Pharmaceutical GLP-1 agonists treat type 2 diabetes by mimicking the GLP-1 hormone. These include Ozempic, Wegovy, Zepbound, and Mounjaro. Although these drugs have existed for almost 20 years, recent variations have recorded significant weight loss successes.</span><span data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"> </span></p>
<hr />
<p><a href="https://finaffiliates.us20.list-manage.com/subscribe/post?u=e0dd4d77c259eb270712a4eeb&id=fd200b8f75&v_id=4291&f_id=00946ce6f0" target="_blank" rel="noreferrer noopener"><span lang="EN-GB" xml:lang="EN-GB" data-contrast="none"><span data-ccp-char>Don’t miss out the latest news, subscribe to </span><span data-ccp-char>LeapRate’s</span><span data-ccp-char> newsletter</span></span></a><span data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"> </span></p>
<hr />
<p><span data-contrast="auto">An in-depth Bank of America report published in October 2023 sparked a sell-off frenzy as it predicted sales drops for sectors such as the food industry due to decreased cravings. Despite these doom prophecies, restaurant franchises such as McDonald’s (MCD), Restaurant Brand International (QSR), and Wendy’s (WEN) have since improved their financial performance.</span><span data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"> </span></p>
<p><span data-contrast="auto">Markets feared weight loss and insulin control would reduce the need for bariatric procedures and monitoring gadgets such as blood glucose testers. The opposite, however, happened, as people became keener to track their health journeys.</span><span data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"> </span></p>
<p>The post <a rel="nofollow" href="https://www.leaprate.com/forex/market-news/impact-of-weight-loss-drugs-on-medical-devices-and-food-and-beverage-stocks-waning/">Impact of weight loss drugs on medical devices and food and beverage stocks waning</a> appeared first on <a rel="nofollow" href="https://www.leaprate.com">LeapRate</a>.</p>
Leave a Comment